PARP1 and ovarian cancer: Among the reported novel PARP-1 inhibitors, we examined KJ-28d, as shown in Figure 1A, based on the prior demonstrations of its significant inhibitory activity against PARP-1, as well as antitumor activity in BRCA-deficient ovarian cancer cells [21].